Document is current
Any future updates will be listed below
-
Authors
Wee, Christina C. https://orcid.org/0000-0002-0439-5746
Fleishman, Aaron
McCarthy, Ashley C.
Hess, Donald T.
Apovian, Caroline
Jones, Daniel B.
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK073302)
National Institute of Diabetes and Digestive and Kidney Diseases (K24 DK087932)
- License Information
-
More Information
Article History
First Online: 22 February 2019
Compliance with Ethical Standards
: The study was approved by institutional review boards (IRB) at the Beth Israel Deaconess Medical Center, Boston Medical Center, and University of Massachusetts Center for Survey Research (all in Boston, MA).
: One of the authors reports ownership interest in Allurion (DJ). Another author (CA) also reports receiving consulting fees for being on the advisory boards of Nutrisystem, Zafgen, Sanofi-Aventis, Orexigen, EnteroMedics, GI Dynamics, Scientific Intake, Gelesis, Novo Nordisk, SetPoint Health, Xeno Biosciences, Rhythm Pharm, Eisai, and Takeda, and research funding from Aspire Bariatrics, GI Dynamics, Orexigen, Takeda and the Vela Foundation, Gelesis, Energesis, and Coherence Lab; this author also participated in the Takeda Speakers Bureau for the medication Contrave and owned stock in Science-Smart LLC.
